

Product Information

Product ID F8147

CAS No. 129453-61-8

Chemical Name

Synonym

Formula C₃₂H₄₇F₅O₃S

Formula Wt. 606.77

Melting Point


Purity ≥98%

Solubility Soluble in ethanol (>200 mg/mL), DMSO (>20 mg/mL). Insoluble in water. DMF 20 mg/mL, chloroform

Store Temp Ambient

Ship Temp Ambient

Description Fulvestrant is an anti-endocrine compound that exhibits anticancer chemotherapeutic benefit in the treatment of estrogen receptor (ER)-positive breast cancer. Fulvestrant causes degradation of ERs and downregulates ER expression, inhibiting cell growth. Fulvestrant also upregulates expression of UDP glucuronosyltransferase 1A4 (UGT1A4) in cancer cells. Additionally, fulvestrant exhibits some anti-hyperlipidemic benefit in clinical settings, as patients receiving it as a chemotherapeutic also exhibited lower serum levels of total cholesterol and LDL.



Bulk quantities available upon request

Product ID	Size
F8147	5 mg
F8147	25 mg
F8147	100 mg

References Edavana VK, Penney RB, Yao-Borengasser A, et al. Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism. Springerplus. 2013 Nov 20;2:620. PMID: 24298433.

Krell J, Januszewski A, Yan K, et al. Role of fulvestrant in the management of postmenopausal breast cancer. Expert Rev Anticancer Ther. 2011 Nov;11(11):1641-52. PMID: 22050013.

Scott SM, Brown M, Come SE. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer. Expert Opin Drug Saf. 2011 Sep;10(5):819-26. PMID: 21699443

Camerini A, Rondini M, Garrone O, et al. Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients. Cancer Biol Ther. 2009 Aug;8(15):1450-5. PMID: 19556864.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.